{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"3"}]}],"title":"Baseline ECOG Score 0: Post-baseline Score 0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"7"}]}],"title":"Baseline ECOG Score 0: Post-baseline Score 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"}]}],"title":"Baseline ECOG Score 0: Post-baseline Score 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}],"title":"Baseline ECOG Score 0: Post-baseline Score 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"title":"Baseline ECOG Score 0: Post-baseline ECOG Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}],"title":"Baseline ECOG Score 1: Post-baseline Score 0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"44"},{"groupId":"OG002","value":"17"}]}],"title":"Baseline ECOG Score 1: Post-baseline ECOG 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"4"}]}],"title":"Baseline ECOG Score 1: Post-baseline ECOG 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}]}],"title":"Baseline ECOG Score 1: Post-baseline ECOG 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}]}],"title":"Baseline ECOG Score 1: Post-baseline ECOG 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}],"title":"Baseline ECOG Score 1: Post-baseline ECOG Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"title":"Baseline ECOG Score 2: Post-baseline ECOG Missing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"108"},{"groupId":"OG002","value":"38"}],"units":"Participants"}],"description":"ECOG is a 6-point scale (0-5) used to assess participants functional status, where, 0= Fully active, able to carry on all pre-disease performance without restriction; 1= restricted in physically strenuous activity but ambulatory \\& able to carry out work of a light or sedentary nature, e.g., light housework, office work; 2= ambulatory \\& capable of all self-care but unable to carry out any work activities. Up \\& about more than 50% of waking hours; 3= capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4= completely disabled, cannot carry on any self-care, totally confined to bed or chair; 5= dead.","groups":[{"description":"Participants received platinum-containing anticancer treatment regimens (with or without pembrolizumab) at the study center as chosen by the treating investigator based on NSCLC histology. Participants with NSCLC of non-squamous histology received carboplatin + pemetrexed or cisplatin + pemetrexed or pembrolizumab + carboplatin + pemetrexed or pembrolizumab + cisplatin + pemetrexed. Participants with NSCLC of squamous histology received carboplatin or cisplatin + gemcitabine or carboplatin + paclitaxel/nab-paclitaxel + pembrolizumab until PD or for up to a maximum of 2 years.","id":"OG000","title":"Arm A: Treatment Period- SOC"},{"description":"Participants received pralsetinib, 400 mg, QD on Day 1 of each cycle until PD, PTAP, pralsetinib was no longer available, unacceptable toxicity, non-compliance, withdrawal of consent, closure of the study by the sponsor, or death, whichever occurred first (cycle length=21 days).","id":"OG001","title":"Arm B: Treatment Period- Pralsetinib"},{"description":"Participants with confirmed PD as confirmed by blinded independent central review (BICR) in Arm A crossed over to receive pralsetinib, 400 mg, orally, QD on Day 1 of each cycle until PD, PTAP, pralsetinib was no longer available, unacceptable toxicity or death, whichever occurred first (cycle length=21 days).","id":"OG002","title":"Arm C: Crossover Period- Pralsetinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety-evaluable population included all participants who receive any amount of any study drug. As specified in the protocol, assessment of this outcome measure was limited to the treatment period, as the objective was to compare pralsetinib with SOC platinum-containing anticancer treatment regimens.","reportingStatus":"POSTED","timeFrame":"Baseline up to 50 months","title":"Number of Participants With Change From Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score","type":"SECONDARY","unitOfMeasure":"Participants"}